Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

被引：0
|
作者：
Jorge E. Romaguera
M. Alma Rodriguez
Fredrick B. Hagemeister
Peter McLaughlin
Jose Rodriguez
Alejandro Preti
Anas Younes
Andreas H. Sarris
Fernando Cabanillas
机构：
[1] University of Texas M.D. Anderson Cancer Center,Department of Lymphoma
来源：
Investigational New Drugs | 1999年 / 17卷
关键词：
relapsed NHL; paclitaxel; MINT chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose: Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL).
引用
收藏
页码：187 / 192
页数：5
相关论文
共 50 条
  • [41] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
  • [42] Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Heyman, Benjamin
    Rizzieri, David
    Adams, David J.
    De Castro, Carlos
    Diehl, Louis
    Li, Zhiguo
    Moore, Joseph
    Beaven, Anne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10): : 679 - 686
  • [43] Treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of a taxane, cyclophosphamide and rituximab.
    Krämer, A
    Zoz, M
    Krasniqi, F
    Görner, M
    Leo, E
    Ho, AD
    BLOOD, 2001, 98 (11) : 135A - 135A
  • [44] Salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab: Preliminary results of a multicenter phase it trial.
    Mey, U
    Flieger, D
    Birkmann, J
    Ho, A
    Huhn, D
    Kaiser, U
    Ko, Y
    Kraemer, A
    Neubauer, A
    Wilhelm, M
    Hahn, C
    Haarmann, G
    Glasmacher, A
    Schmidt-Wolf, I
    BLOOD, 2002, 100 (11) : 309B - 309B
  • [45] MESNA IFOSFAMIDE, MITOXANTRONE, ETOPOSIDE, BLEOMYCIN, VINCRISTINE, PREDNISONE (MINE-BOP) COMBINATION CHEMOTHERAPY IN THE TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS-LYMPHOMA
    DINCOL, D
    ICLI, F
    KARAOGUZ, H
    CAY, F
    ARICAN, A
    DEMIRKAZIK, A
    AKBULUT, H
    ACTA ONCOLOGICA, 1995, 34 (07) : 937 - 940
  • [46] Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Younes, A
    Preti, HA
    Hagemeister, FB
    McLaughlin, P
    Romaguera, JE
    Rodriguez, MA
    Samuels, BI
    Palmer, JL
    Cabanillas, F
    ANNALS OF ONCOLOGY, 2001, 12 (07) : 923 - 927
  • [47] Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study
    Kamdar, Manali
    Augustson, Bradley
    Rok, Young
    Edwards, James
    Hertzberg, Mark
    Johnston, Amanda
    Kim, Jin Seok
    Kroschinsky, Frank P.
    Smith, Sonali M.
    Stevens, Don A.
    Monnet, Annabelle
    Zhao, Ye
    Nouet, Yann
    Marinova, Viktoriya
    BLOOD, 2020, 136
  • [48] High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma
    Wang, WS
    Tzeng, CH
    Chiou, TJ
    Liu, JH
    Hsieh, RK
    Yen, CC
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (03) : 154 - 157
  • [49] Phase II study of combination immunotherapy with interleukin-2 (IL-2) and rituximab in patients with relapsed or refractory follicular non-Hodgkin's lymphoma (NHL).
    Friedberg, JW
    Neuberg, D
    Gribben, JG
    Canning, C
    Daley, JF
    Kuhlman, C
    Koval, M
    Donovan, J
    Soiffer, RJ
    Freedman, AS
    BLOOD, 2000, 96 (11) : 730A - 731A
  • [50] A Phase I Study of Panobinostat in Combination With ICE (Ifosfamide, Carboplatin and Etoposide) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 5 - 6
12345